Evaluating the therapeutic potential of genetically engineered probiotic Zbiotics (ZB183) for non-alcoholic steatohepatitis (NASH) management <i>via</i> modulation of the cGAS-STING pathway-Reference-Cited by-同舟云学术

Evaluating the therapeutic potential of genetically engineered probiotic Zbiotics (ZB183) for non-alcoholic steatohepatitis (NASH) management via modulation of the cGAS-STING pathway

Published:2024 Issue: Volume: Page:
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Saad Maha¹²³^ORCID,Ibrahim Walaa³,Hasanin Amany Helmy⁴,Elyamany Aya Magdy⁵,Matboli Marwa⁶^ORCID

Affiliation:

1. Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Modern University for Technology and Information, Cairo, Egypt

2. Biomedical Research Department, Faculty of Medicine, Modern University for technology and information, Cairo, Egypt

3. Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt

4. Clinical Pharmacology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt

5. Anatomic Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

6. Departement of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt

Abstract

ZBiotics administration in the NASH model downregulated the RNA panel (MAPK3, EDN1, TNF, miR-6888-5p, lncRNA RABGAP1L-DT-206), restored intestinal barrier integrity, reduced hepatic inflammation, and improved lipid profiles and liver enzymes.

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00477A

Reference130 articles.

1. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD

2. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

3. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes

4. Pathogenesis of Nonalcoholic Steatohepatitis

5. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis